1-3 of 3
Jerry Klein
Close
Sort by
Journal Articles

A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM)

Andrew Belch, MD, Atul Sharma, MD, Andrew Spencer, MD, Stefano Tarantolo, Nizar J Bahlis, MD, Dinesh Doval, MD, Gilles Gallant, BPharm, PhD, Elizabeth Kumm, MS, Jerry Klein, PhD, Asher A. Chanan-Khan
Journal: Blood
Blood (2010) 116 (21): 5031.
https://doi.org/10.1182/blood.V116.21.5031.5031
Published: 2010
Journal Articles

Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).

Anas Younes, MD, Julie M. Vose, MD, Andrew D. Zelenetz, MD, PhD, Mitchell R. Smith, MD, PhD, Howard Burris, MD, Stephen Ansell, MD, PhD, Jerry Klein, PhD, Elizabeth Kumm, MS, Myron Czuczman, MD
Journal: Blood
Blood (2005) 106 (11): 489.
https://doi.org/10.1182/blood.V106.11.489.489
Published: 2005
Journal Articles

Tumor Targeting, Dosimetry and Clinical Response Data for Lymphorad-131 (LR131; Iodine I-131 Labeled B-Lymphocyte Stimulator) in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma.

Andrew Belch, Alexander McEwan*, Joanne Hewitt*, Terence Riauka, Michael Stabin*, Aaron Brill*, Gilles Gallant, Lara Blake*, Jerry Klein
Journal: Blood
Blood (2004) 104 (11): 750.
https://doi.org/10.1182/blood.V104.11.750.750
Published: 2004